Long-chain fatty acid analogues suppress breast tumorigenesis and progression

Cancer Research

Volumn 74, Issue 23, 2014, Pages 6991-7002

  Gluschnaider, Udi ^a   Hertz, Rachel ^a   Ohayon, Sarit ^a   Smeir, Elia ^a   Smets, Martha ^a   Pikarsky, Eli ^a   Bar Tana, Jacob ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BETA CATENIN; BETA,BETA'TETRAMETHYLHEXADECANEDIOIC ACID; CASPASE 3; CD34 ANTIGEN; DASATINIB; FATTY ACID DERIVATIVE; GELATINASE B; LONG CHAIN FATTY ACID DERIVATIVE; PROTEIN KINASE P60; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; FATTY ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER; BREAST TUMOR; CANCER INHIBITION; CARBOHYDRATE RESTRICTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; INFANT; KETOGENIC DIET; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; OLIGOMERIZATION; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEATORRHEA; TREATMENT RESPONSE; WEIGHT GAIN; ANIMAL; BREAST NEOPLASMS; CARCINOGENESIS; CELL DIFFERENTIATION; DISEASE COURSE; DRUG EFFECTS; GENETICS; LOW CARBOHYDRATE DIET; LUNG TUMOR; METABOLISM; ONCOGENE SRC; PATHOLOGY; PROCEDURES; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DIET, CARBOHYDRATE-RESTRICTED; DISEASE PROGRESSION; FATTY ACIDS; FEMALE; GENES, SRC; HUMANS; LUNG NEOPLASMS; MALE; MICE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84917710704     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0385     Document Type: Article

References (50)

1. Fluck MM, Schaffhausen BS. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev 2009;73: 542-63.
2. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-26.
3. Zhou AY, Ichaso N, Adamarek A, Zila V, Forstova J, Dibb NJ, et al. Polyomavirus middle T-antigen is a transmembrane protein that binds signaling proteins in discrete subcellular membrane sites. J Virol 2011;85:3046-54.
4. Carmichael GG, Schaffhausen BS, Dorsky DI, Oliver DB, Benjamin TL. Carboxy terminus of polyoma middle-sized tumor antigen is required for attachment to membranes, associated protein kinase activities, and cell transformation. Proc Natl Acad Sci U S A 1982; 79:3579-83.
5. Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997; 8:1267-76.
6. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JEJr. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998;18:2553-8.
7. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004;23: 8017-23.
8. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 2012;30:1005-14.
9. Yang Y, Jiang B, Huo Y, Primo L, Dahl JS, Benjamin TL, et al. Shp2 suppresses PyMT-induced transformation in mouse fibroblasts by inhibiting Stat3 activity. Virology 2011;409:204-10.
10. Arulanandam R, Geletu M, Raptis L. The simian virus 40 large tumor antigen activates cSrc and requires cSrc for full neoplastic transformation. Anticancer Res 2010;30:47-53.
11. Vultur A, Arulanandam R, Turkson J, Niu G, Jove R, Raptis L. Stat3 is required for full neoplastic transformation by the Simian Virus 40 large tumor antigen. Mol Biol Cell 2005;16:3832-46.
12. Ottenhoff-Kalff AE, Rijksen G, van Beurden EA, Hennipman A, Michels AA, Staal GE. Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 1992;52:4773-8.
13. Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, et al. The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia 2013;15:848-62.
14. Bjorge JD, Pang AS, Funnell M, Chen KY, Diaz R, Magliocco AM, et al. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. PLoS ONE 2011;6:e19309.
15. Klement RJ, Kammerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab 2011;8:75.
16. Fine EJ, Segal-Isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition 2012;28:1028-35.
17. Tognon CE, Sorensen PH. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 2012;16:33-48.
18. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11: 325-37.
19. Ferguson RD, Gallagher EJ, Scheinman EJ,Damouni R, LeRoith D. The epidemiology and molecular mechanisms linking obesity, diabetes, and cancer. Vitam Horm 2013;93:51-98.
20. Gonzalez-Baro MR, Lewin TM, Coleman RA. Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action. Am J Physiol Gastrointest Liver Physiol 2007;292:G1195-9.
21. Bar-Tana J, Ben-Shoshan S, Blum J, Migron Y, Hertz R, Pill J, et al. Synthesis and hypolipidemic and antidiabetogenic activities of beta, beta,beta',beta'-tetrasubstituted, long-chain dioic acids. J Med Chem 1989;32:2072-84.
22. Bar-Tana J, Rose-Kahn G, Frenkel B, Shafer Z, Fainaru M. Hypolipidemic effect of beta, beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in normal and nephrotic rats. J Lipid Res 1988; 29:431-41.
23. Mayorek N, Kalderon B, Itach E, Bar-Tana J. Sensitization to insulin induced by beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) in obese Zucker rats in vivo. Diabetes 1997;46:1958-64.
24. Russell JC, Amy RM, Graham SE, Dolphin PJ, Wood GO, Bar-Tana J. Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by beta, beta'-tetramethylhexadecanedioic acid (MEDICA 16). Arterioscler Thromb Vasc Biol 1995;15:918-23.
25. Qian B, Deng Y, Im JH, Muschel RJ, Zou Y, Li J, et al. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE 2009;4:e6562.
26. Zatara G, Hertz R, Shaked M, Mayorek N, Morad E, Grad E, et al. Suppression of FoxO1 activity by long-chain fatty acyl analogs. Diabetes 2011;60:1872-81.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
28. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11.
29. Shi B, Liang J, Yang X, Wang Y, Zhao Y, Wu H, et al. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol 2007;27:5105-19.
30. Li X, Gonzalez ME, Toy K, Filzen T, Merajver SD, Kleer CG. Targeted overexpression of EZH2 in the mammary gland disrupts ductal morphogenesis and causes epithelial hyperplasia. Am J Pathol 2009; 175:1246-54.
31. Chase A, Cross NC. Aberrations of EZH2 in cancer. Clin Cancer Res 2011;17:2613-8.
32. Zeidler M, Kleer CG. The Polycomb group protein enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol 2006;37:219-23.
33. Borowsky AD, Namba R, Young LJ, Hunter KW, Hodgson JG, Tepper CG, et al. Syngeneic mouse mammary carcinoma cell lines: twoclosely related cell lines with divergent metastatic behavior. Clin Exp Metastasis 2005;22:47-59.
34. Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011;17:5546-52.
35. Kemble DJ, Sun G. Direct and specific inactivation of protein tyrosine kinases in the Src and FGFR families by reversible cysteine oxidation. Proc Natl Acad Sci U S A 2009;106:5070-5.
36. Giannoni E, Buricchi F, Raugei G, Ramponi G, Chiarugi P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol 2005;25: 6391-403.
37. Giannoni E, Taddei ML, Chiarugi P. Src redox regulation: again in the front line. Free Radic Biol Med 2010;49:516-27.
38. Tang H, Hao Q, Rutherford SA, Low B, Zhao ZJ. Inactivation of SRC family tyrosine kinases by reactive oxygen species in vivo. J Biol Chem 2005;280:23918-25.
39. Allen BG, Bhatia SK, Buatti JM, Brandt KE, Lindholm KE, Button AM, et al. Ketogenic diets enhance oxidative stress and radio-chemotherapy responses in lung cancer xenografts. Clin Cancer Res 2013;19:3905-13.
40. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011;17:461-9.
41. Wang X, Wang G, Zhao Y, Liu X, Ding Q, Shi J, et al. STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro. J Biomed Res 2012;26:325-35.
42. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 1994;8:23-32.
43. Creedon H, Brunton VG. Src kinase inhibitors: promising cancer therapeutics? Crit Rev Oncog 2012;17:145-59.
44. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, et al. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 2009;69:3842-9.
45. Hebbard L, Cecena G, Golas J, Sawada J, Ellies LG, Charbono A, et al. Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene 2011;30:301-12.
46. Canel M, Serrels A, Miller D, Timpson P, Serrels B, Frame MC, et al. Quantitative in vivo imaging of the effects of inhibiting integrin signaling via Src and FAK on cancer cell movement: effects on E-cadherin dynamics. Cancer Res 2010;70:9413-22.
47. Masuda M, Wakasaki T, Suzui M, Toh S, Joe AK, Weinstein IB. Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? Curr Cancer Drug Targets 2010;10: 117-26.
48. Samovski D, Kalderon B, Yehuda-Shnaidman E, Bar-Tana J. Gating of the mitochondrial permeability transition pore by long chain fatty acyl analogs in vivo . J Biol Chem 2010;285:6879-90.
49. Schonfeld P, Wojtczak L. Fatty acids as modulators of the cellular production of reactive oxygen species. Free Radic Biol Med 2008; 45:231-41.
50. Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta 2006; 1757:509-17.